Directors' Dealings

Omega Diagnostics Group PLC
31 August 2007


Omega Diagnostics Group PLC

31 August 2007


Omega Diagnostics Group PLC ('Omega' or 'the Company')

Directors Shareholdings & Issue of Equity

Omega Diagnostics Group PLC announces that following its share consolidation and
capital reorganization (the 'Share Consolidation' and the 'Capital
Reorganisation' respectively), 9,684,470 new Ordinary Shares of 4 pence each ('
New Ordinary Shares') have today been admitted to AIM (the 'First Admission').
Application has been made for a further 5,191,223 New Ordinary Shares to be
admitted to AIM, which is expected to become effective on 3 September 2007 (the
'Second Admission').

As part of the placing related to the acquisitions of Genesis Diagnostics
Limited and Cambridge Nutritional Sciences Limited announced on 6 August 2007
and approved by shareholders at the EGM of the Company yesterday 
(the 'Placing'), David Evans, Non-Executive Chairman and Andrew Shepherd, 
Chief Executive Officer of the Company have today purchased New Ordinary Shares 
at the placing price of 30p per share.  The number of New Ordinary Shares 
purchased by each Director and their resultant holding of New Ordinary Shares in 
the Company is set out below:

                              No. of New        Interest in New   Interest in total   Interest in total
                              Ordinary Shares   Ordinary Shares   issued share        issued share
                              purchased as part following the     capital following   capital following
                              of the Placing    Placing           First Admission     Second Admission

David Evans, Non-Executive    100,000           100,000           1.03%               0.67%
Chairman

Andrew Shepherd, Chief        100,000           902,568           9.32%               6.07%
Executive Officer


In addition, in accordance with the details of the Share Consolidation set out
in the Admission Document published on 3 August 2007, David Evans yesterday
purchased 25 non-consolidated Ordinary Shares of 1p each in the Company ('Old
Ordinary Shares') at the price of 1p per Old Ordinary Share, being the par value
of the Old Ordinary Shares.  This was in order to increase the issued share
capital of the Company to a number divisible by 40 prior to the Share
Consolidation becoming effective.  Following this transaction, David Evans held
less than 0.01% of yesterday's issued share capital.

Following the implementation of the Share Consolidation, these 25 Old Ordinary
Shares are now a fraction of a New Ordinary Share and have been aggregated with
the fractions of New Ordinary Shares to which other fractional shareholders of
the Company are entitled so as to form full New Ordinary Shares and will be sold
in the market for the benefit of the Company.  In total there are 19 New
Ordinary Shares resulting from fractional entitlements to New Ordinary Shares.

The issue of 25 Old Ordinary Shares of 1p each to David Evans has resulted in
one additional New Ordinary Share following aggregation with other fractional
entitlements after the Share Consolidation.  Application has been made for this
additional New Ordinary Share to be admitted to trading on AIM, which is
expected to become effective on 6 September 2007.  Following Admission of this
additional New Ordinary Share the Company's issued share capital will consist of
14,875,694 New Ordinary Shares.

Contacts:

Omega Diagnostics Group PLC
Tel: [phone]

Andrew Shepherd, Chief Executive
Kieron Harbinson, Finance Director
www.omegadiagnostics.com

Landsbanki Securities (UK) Limited
Nominated Adviser & Broker
Tel: [phone]

Thilo Hoffmann/Simon Brown, Corporate Finance

Parkgreen Communications Limited
Ben Knowles
T. 020 7479 7933
Mob. [phone]
[e-mail]


                      This information is provided by RNS
            The company news service from the London Stock Exchange